The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 23, 2015
Filed:
Nov. 26, 2012
Applicant:
Bayer Intellectual Property Gmbh, Monheim, DE;
Inventors:
Nico Bräuer, Falkensee, DE;
Anne Mengel, Berlin, DE;
Ulrike Charlotte Röhn, Berlin, DE;
Andrea Rotgeri, Berlin, DE;
Bernd Buchmann, Hohen Neuendorf, DE;
Bernhard Lindenthal, Berlin, DE;
Antonius Ter Laak, Berlin, DE;
Assignee:
Bayer Intellectual Property GmbH, Monheim, DE;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/397 (2006.01); A61K 31/5377 (2006.01); A61K 31/505 (2006.01); A61K 31/445 (2006.01); C07D 413/02 (2006.01); C07D 239/02 (2006.01); C07D 211/68 (2006.01); C07D 231/56 (2006.01); C07D 417/14 (2006.01); C07D 401/14 (2006.01); C07D 413/14 (2006.01); C07D 401/06 (2006.01); C07D 403/06 (2006.01); C07D 403/14 (2006.01); C07D 407/14 (2006.01); A61K 45/06 (2006.01); A61K 31/416 (2006.01); A61K 31/454 (2006.01); A61K 31/4545 (2006.01); A61K 31/506 (2006.01); A61K 31/513 (2006.01); C07D 405/14 (2006.01);
U.S. Cl.
CPC ...
C07D 417/14 (2013.01); C07D 401/14 (2013.01); C07D 413/14 (2013.01); C07D 401/06 (2013.01); C07D 403/06 (2013.01); C07D 403/14 (2013.01); C07D 407/14 (2013.01); A61K 45/06 (2013.01); A61K 31/416 (2013.01); A61K 31/454 (2013.01); A61K 31/4545 (2013.01); A61K 31/506 (2013.01); A61K 31/513 (2013.01); A61K 31/5377 (2013.01); C07D 405/14 (2013.01);
Abstract
The present invention relates to novel 2H-indazoles of the general formula (I), methods for the preparation thereof and the use thereof for the production of pharmaceutical agents for the treatment of diseases and indications which are linked with the EP-receptor.